NIH Guide, Volume 26, Number 38, November 21, 1997

RFA:  HD-98-002


National Institute of Child Health and Human Development

Letter of Intent Receipt Date:  January 12, 1998
Application Receipt Date:  March 17, 1998


The National Institute of Child Health and Human Development (NICHD) plans to
continue to support an ongoing cooperative Network of Pediatric Pharmacology
Research Units (PPRU) that serve as a resource for studies of drug action and
disposition in infants, children and adolescents.  These studies will be
conducted by pediatric clinical pharmacologists, either cooperatively with
investigators at other Units in the Network, collaboratively with pharmaceutical
companies, or independently with other support.  The goals of studies conducted
by the network are: 1) to provide the clinical data on new drugs and drugs
already on the market that are necessary  for U.S. Food and Drug Administration
(FDA) approval for use in children; and 2) to investigate the pharmacology of new
molecular entities and biopharmaceuticals for use in children.  The Network will
also serve as a resource for the training of health professionals in pediatric
pharmacology and clinical trials.  It is anticipated that up to 10 clinical
centers will be involved in the program.


The Public Health Service (PHS) is committed to achieving the health promotion
and disease prevention goals of "Healthy People 2000," a PHS-led national
activity for setting priorities.  This Request for Applications (RFA), Network
of Pediatric Pharmacology Research Units, is related to the priority areas of
food and drug safety and maternal and infant health.  Copies of "Healthy People
2000" (Full Report: Stock No. 017-001-00474-0, or Summary Report: Stock No.
017-001-00473-1) are available through the Superintendent of Documents,
Government Printing Office, Washington, DC 20402-9325 (telephone 202-512-1800).


Applications may be submitted by domestic non-profit organizations, public and
private.  Awards will be made to children's hospitals or their equivalent or to
educational institutions with accredited medical schools, within the United
States.  Each PPRU must be an identifiable unit within its institution, its
Principal Investigator reporting to the chief of pediatrics or to the chairperson
of the pediatrics department.  Racial/ethnic minority individuals, women, and
persons with disabilities are encouraged to apply as principal investigators. 
Current Network participants are eligible for competing continuation awards. The
applicant institution must also meet the standard eligibility requirements for
research grants established in the Public Health Service Grants Policy Statement
# (OASH) 90-50,000, Rev. 4/1/94.

There should be at the applicant institution an ongoing program of excellence in
clinical pharmacology, preferably with an emphasis on pediatric applications. 
The quality of this program must be evident from the receipt by its staff of
research support in peer-reviewed competition, or from their consistent record
of publication in peer-reviewed research journals.  In addition, the applicant
institution must have available and accessible a sufficient number of eligible
research subjects in the pediatric age groups:  newborns, infants, children,
pre-adolescents, and adolescents.  This is an essential component of the network
and must be spelled out in detail in the application.  (See Special Requirements)


The administrative and funding instrument to be used for this program will be a
cooperative agreement (U01), an assistance mechanism (rather than an acquisition
mechanism), in which substantial NIH scientific and/or programmatic involvement
with the awardee is anticipated during performance of the activity.  Under the
cooperative agreement, the NIH purpose is to support and stimulate the
recipient's activity by working jointly with the award recipients in a partner
role.  Details are discussed later in this document under the section þTerms of

The total project period for applications submitted in response to the present
RFA may not exceed five years.  The anticipated award date is January 1, 1999.


It is expected that up to 10 applications, including competing continuation and
new awards, will be funded. An estimated total cost of $3,000,000 will be
available for the first year.  Therefore, the maximum total cost request (first
year) for individual applications should not exceed $300,000.The number of awards
is dependent on the receipt of a sufficient number of applications of high
scientific merit.  



Federal law and the regulations of the FDA require that drugs be tested for
safety and efficacy before they are approved for clinical use.  This testing must
take place in all populations in which the drug will be employed.  Since both the
qualitative and quantitative aspects of pharmacodynamics and pharmacokinetics are
different in immature individuals, studies must be conducted in infants and
children before a drug can be approved for use in them.

Several practical problems discourage the testing of drugs in children.  These
include the unforeseeable nature of some clinical responses in immature
individuals; the possibility of catastrophic unanticipated reactions; the threat
of effects on growth or health long after completion of the drug administration;
the difficulty in predicting dose- response relationships by extrapolation from
data obtained in adults; the ethical problems of conducting nontherapeutic
research in children; the awkwardness of procedures for obtaining informed
parental consent and children's assent in children; the lack of a suitable
infrastructure for the conduct of pediatric pharmacology research; the high cost
of pediatric studies; and the absence of a financial incentive for the
pharmaceutical industry to conduct pediatric pharmaceutical trials if children
are a minority of the population for which the drug might be prescribed.

The result of these practical problems and the regulatory requirements is that
more than three-quarters of the drugs marketed in the United States, including
many of the most useful agents in modern therapy, are not approved as safe and
effective for use in children.  Since the provision of pediatric care without the
use of these agents would be unacceptable, they are commonly administered
"off-label" (without specific FDA approval) by pediatricians, anesthesiologists,
general practitioners, surgeons, and others.  Under these conditions the child
is at risk of an inadequate therapeutic response or some unanticipated adverse
reaction.  Physicians can face medicolegal actions as a result of such accidents,
but they can also risk suit for failure to utilize an effective drug for a
child's illness, even if that drug does not have specific FDA approval for use
in children.

Modern pediatric pharmacology is a sophisticated clinical discipline capable of
carrying out the studies necessary for the safe and ethical evaluation of drugs
in children.  Pursuit of such studies, however, is limited by the scarcity of
available facilities in which to follow children receiving drugs and to collect
data in a systematic way, as well as the insufficient number of qualified
clinical investigators interested in this problem.  

In response to the need for appropriate drug therapy studies in pediatric
patients, the NICHD established the Pediatric Pharmacology Research Unit Network
(PPRU) in 1994.
Seven university units were selected among respondents to an RFA. The Network
Steering Committee (NSC) which consists of  principal investigators, NICHD staff
and an outside chairman, selected protocols for study by the network.

In 1995 the FDA implemented a regulation which allows labeling of drugs for
pediatric use based on appropriate studies in adults and additional
pharmacokinetics, pharmacodynamics and safety studies in pediatric patients if
the course of their disease and drug effects are similar in children and adults. 
This regulation was designed to encourage pediatric labeling.  By April 1997
pharmaceutical companies were required to submit information about the pediatric
use of their products, frequency of use, therapeutic significance and safety
risks.  The FDA issued new regulations in August 1997, to be effective six months
later, requiring pediatric studies of certain new drugs.

An overwhelming number of drugs lacking FDA approval in pediatrics continue to
be used in infants and children.  Because of this widespread use of unapproved
drugs, studies leading to pediatric labeling remain a priority for the next
funding cycle of this Network.

The training of pediatric clinical pharmacologists and health care professionals
involved in pediatric drug trials remains a priority because of the increased
demand and scarcity of qualified individuals. 

Objectives and Scope

The purpose of this RFA is to continue the ongoing multicenter program of
Pediatric Pharmacology Research Units for another award period of five years.

Each PPRU will have five specific aims:

(1) To provide a locus for the conduct of  studies in bioavailability,
formulations, drug metabolism, pharmacokinetics, pharmacodynamics, safety and
effectiveness of new drugs and drugs already in the market. These studies may be
investigator initiated or they may originate with pharmaceutical companies or
Contract Research Organizations (CROs).

(2) To gather or promote the accrual of the necessary clinical data for pediatric
age- specific labeling of drugs. 

(3) To conduct research on new pediatric therapeutic modalities, including: a)
molecular approaches to the treatment of diseases, b) application of new
technology to pharmacodynamic studies and drug delivery systems, c) development
of pediatric formulations, and d) validation of new endpoints or surrogate
(4) To conduct studies on the developmental characteristics and genetic
polymorphism of drug metabolizing enzymes, pharmacokinetic modeling, and
simulation technology.
(5) To provide a teaching environment in which pediatricians, pharmacists, nurses
and others can gain supervised experience in pediatric clinical trials and
training in evidence-based pediatric pharmacology.

It is expected that most of the studies conducted in the PPRU network will be
clinical and for the pediatric age group.  Nevertheless, pre-clinical studies may
sometimes be conducted (with other support) in a Unit's core laboratory if these
are important as preliminaries or adjuncts to clinical projects in research areas
that conform to guidelines developed by the Network Steering Committee (NSC) with
the advice of the Advisory Board (see below).  Similarly, limited clinical
studies in adults may sometimes justify PPRU support if they are necessary for
adapting existing protocols to children.  It is expected that principal
investigators will cooperate with the NICHD Program Coordinator in identifying
research areas of high priority for the Network.

It is expected that all participating units will be involved in collaborative
clinical trials of drugs with other units in the Network through protocols
determined by consensus and that individual units will have different and
complementary research strengths in pediatric clinical pharmacology.

Local protocols will be permitted only if they fulfill objectives 3 or 4 or if
the proposed study would provide the basis for an anticipated Network protocol. 
All local protocols must be approved by the NSC.  Pharmacokinetics studies
requested by pharmaceutical companies for pediatric labeling purposes and
assigned by the NSC to a single Unit are not considered local protocols.

Guidance and Management Structures

The management of the PPRU Network includes four committees:(1) The Network
Steering Committee,(2) an Advisory Board, (3) a Data Safety and Monitoring
Committee and (4) an Utilization Review Committee. The roles of these committees
are defined in the section Terms and Conditions of this RFA. 


These special Terms and Conditions of Award are in addition to, and not in lieu
of, otherwise applicable OMB administrative guidelines, HHS grant administration
regulations at 45 CFR Part 74, and other HHS, PHS, and NIH grant administration
policies and procedures.

The administrative and funding instrument used for this program is a cooperative
agreement, an "assistance" mechanism (rather than "acquisition" mechanism) in
which substantial NIH scientific and/or programmatic involvement with the awardee
is anticipated during performance of the activity. Under the cooperative
agreement, the NIH purpose is to support/or stimulate the recipient's activity
by involvement in and otherwise working jointly with the award recipient in a
partner role, but it is not to assume direction, prime responsibility, or a
dominant role in the activity. Consistent with this concept, the dominant role
and prime responsibility for the activity resides with the awardee(s) for the
project as a whole, although specific tasks and activities in carrying out the
studies will be share among the awardees and the NICHD staff.

Awardee Responsibilities

The PI is responsible for developing and maintaining the PPRU as an institutional
and national resource and for overseeing the work of  the associate clinical
pharmacologist and other members of the Unit staff.  It is expected that the PI
will be active in conducting research within the Unit and in negotiating support
from proprietary pharmaceutical organizations.  The PI may be responsible for
industry-sponsored Network protocols. The PI will assist other investigators in
conducting PPRU research protocols.  The PI will attend the meetings of the
Network Steering Committee and participate in its deliberations. Each PI will
have primary responsibility to define objectives and approaches and to plan,
conduct, analyze, and publish results, interpretations, and conclusions of
his/her studies.  For network collaborative protocols, this responsibility will
be shared with other network members and the PPRU Program Coordinator.  The
awardees retain custody of and primary rights to the data developed under those
awards, subject to government rights of access, consistent with current HHS, PHS,
and NIH policies.  Awardees must be willing to participate and collaborate with
other awardees and with NICHD staff. Awardees will be required to accept and
implement common protocols and procedures approved by the Network Steering

NICHD Responsibilities

  The NICHD Program Coordinator is responsible for the overall scientific
administration of the PPRU Network.This role will include the following:
oversight to assure the scientific merit of studies, interventions and trials
done under this initiative; assistance in the efficient conduct of studies,
interventions and trials, including ongoing review of progress, possible
redirection of activities to improve performance, and frequent communication with
other members of the Steering Committee; and initiation of a decision to modify
or terminate a study based on the advice of the Data Safety and Monitoring
Committee, the Advisory Board, and/or the Steering Committee.  
The NICHD reserves the right to terminate or curtail a study (or an individual
award) in the event of substantial shortfall in participant recruitment, follow-
up, data reporting, quality control or other major breach of a protocol; a study
reaches a major study endpoint substantially before schedule with persuasive
statistical significance; qualified scientific investigators are not available
to participate in the study; an awardee's nonparticipation in the committee/group
activities; or human subject ethical issues that may dictate a premature

Collaborative Responsibilities

The management of the PPRU Network includes four committees:

1) The Network Steering Committee (NSC) will be responsible for protocol
development and review assisted by the Advisory Board and by a Data Safety and
Monitoring Committee (see below).  The NSC will have responsibility for the
conduct of protocols, preparation of publications, update of  Network Policies
and Procedures and analysis of reports prepared by the Utilization Review

The Network Steering Committee will consist of the Principal Investigators,the
NICHD Program Coordinator and a non-voting FDA representative.  The NSC will be
chaired by a non-voting outside chairperson selected by the NICHD.  The members
of the NSC will meet at least quarterly and communicate biweekly by formal
conference calls.

2) An Advisory Board  will advice the NSC on the identification and
prioritization of drugs for study and recommend research initiatives.

The Advisory Board chosen by the NICHD with the advice of the Steering Committee
will be composed of individuals with expertise in clinical trials and drug
development in children representing the Center for Drug Evaluation (CDER)FDA,the
Committee on Drugs of the American Academy of Pediatrics, the Pediatric Committee
of the Pharmaceutical Research and Manufacturers of America, and the Pediatric
Committee of the US Pharmacopeia. Ad hoc members for evaluation of quality of
science and of specific research initiatives will be appointed by the NICHD.The
research initiatives necessary to fulfill objectives 3 and 4 of this RFA will be
approved by the Advisory Board. The NICHD Program Coordinator will serve as
Executive Secretary of the Advisory Board, reporting findings to the Steering
Committee and protocol investigators.

3)  A Data Safety and Monitoring Committee will monitor the safety of ongoing
trials in investigator initiated trials which do not have pharmaceutical company
sponsorship.  The Committee will be established by the NICHD and will be composed
of individuals with expertise in the design and conduct of clinical trials,
ethics, and pharmacology.The Data Safety and Safety Committee reports to both the
NICHD and the NSC.

4) Utilization Review Committee

This Committee will evaluate periodically the information provided by the NICHD
Program Coordinator to insure that clinical trials are performed in a cost-
effective and time-expedient manner and to monitor performance measured by
specified parameters set by the NSC.  For pharmacokinetics studies requiring a
small number of patients, the Utilization Committee will ensure that the number
of protocols are evenly distributed among the different units taking into account
factors such recruitment characteristics and protocol complexity.  Members of the
Utilization Committee will include the NICHD Program Coordinator and two
principal investigators selected by the NSC. This Committee will report its
findings to the NSC.


Any disagreement that may arise on scientific matters (within the scope of the
award), between award recipients and the NICHD may be brought to arbitration. An
arbitration panel will be composed of three members-- one person selected by the
individual awardee, one selected by the NICHD Program Coordinator, and a third
person selected by these two members. The decision of the arbitration panel, by
majority vote, will be binding. This special arbitration procedure in no way
affects the awardee's right to appeal an adverse action that is otherwise
appealable in accordance with the PHS regulations at 42 CFR Part 50 Subpart D and
HHS regulation at 45 CFR Part 16.


It is the policy of the NIH that women and members of minority groups and their
subpopulations must be included in all NIH supported biomedical and behavioral
research projects involving human subjects, unless a clear and compelling
rationale and justification is provided that inclusion is inappropriate with
respect to the health of the subjects or the purpose of the research.  This
policy results from NIH Revitalization Act of 1993 (Section 492B of Public Law

All investigators proposing research involving human subjects should read the
"NIH Guidelines For Inclusion of Women and Minorities as subjects in Clinical
Research," which were published in the Federal Register of March 28, 1994 (FR 59
14508-14513), and  in the NIH Guide for Grants and Contracts, Volume 23, Number
11, March 18, 1994.

The usual NIH policies concerning research on human subjects also apply. All
applications for clinical research submitted to the NIH are required to address
these policies. NIH funding components will not award grants or cooperative
agreements that do not comply with these policies. 

Investigators may also obtain copies of the policy from program staff under
INQUIRES. Program staff may also provide additional relevant information
concerning the policy.


Prospective applicants are asked to submit, by January 12, 1998, a letter of
intent that includes a descriptive title of the proposed research, the name,
address, and telephone number of the Principal Investigator, the identities of
other key personnel and participating institutions, and the number and title of
the RFA in response to which the application may be submitted.

Although a letter of intent is not required, is not binding, and does not enter
into the review of subsequent applications, the information that it contains is
helpful in planning. It allows NICHD staff to estimate the potential review
workload and to avoid possible conflict of interest in the review.

The letter of intent is to be sent to:

George P. Giacoia M.D.
Center for Research for Mothers and Children
National Institute of Child Health and Human Development
Building 61E, Room 4B11/MSC 7510
Bethesda, MD  20892-7510
Telephone:  (301) 496-5593
Email:  GiacoiaG@HD01.NICHD.NIH.GOV


The research grant application form PHS 398 (rev. 5/95) is to be used in applying
for these grants.  These forms are available at most institutional offices of
sponsored research and from the Office of Extramural Outreach and Information
Resources, National Institutes of Health, 6701 Rockledge Drive, MSC 7910,
Bethesda, MD 20892-7910, telephone 301/710-0267, Email:

The RFA label available in the PHS 398 application form must be affixed to the
bottom of the face page of the application.  Failure to use this label could
result in delayed processing of the application such that it may not reach the
review committee in time for review.  In addition, the RFA title and number must
be typed on line 2 of the face page of the application form and the YES box must
be marked.

Applicants should follow the instructions included with PHS Form 398 except where
these are at variance with instructions in this RFA.


The requirements for all applicants are as follows:

1) Participants must be based in a Children's Hospital or its equivalent with
access to a sufficient number of eligible research subjects in the pediatric age
group: newborn infants, children, preadolescents and adolescents.  This is an
essential component of the application and must be detailed in the application. 
Statistical information should contain data for both inpatient and outpatient
facilities, including clinics and access to pediatric practices that may
contribute research subjects.

2) Departmental and Institutional commitments to collaborative research must be
documented by letters to the applicant and by evidence of past support and
history of clinical research productivity.

3) Evidence of access to pediatric patients with a wide variety of medical
conditions who are available for drug studies must be provided.  Letters of
commitment by pediatric subspecialists and evidence of previous collaborations
must be provided.  The pediatric subspecialties for which no collaboration is
anticipated should be listed.

4) Evidence of the ability to recruit patients for pediatric drug studies must
be provided.  A list of clinical trials performed during the last four years
should be provided with the following information: a) investigator initiated or
pharmaceutical company sponsored; b) single center or multicenter study; c)
number of centers involved and total number of patients studied; d) type of study
(pharmacokinetics, pharmacodynamics, drug metabolism, bioavailability, efficacy
or safety); e) number of patients studied in the PPRU, f)gender and racial/ethnic
composition of the study subjects; g) whether the study was completed; and h)
major findings of the study.

5) Qualifications of principal investigator and his or her academic productivity
must be documented.  The Principal Investigator (PI) of a PPRU must be an
established pediatric clinical pharmacologist, preferably holding independent
peer-reviewed grant or contract support, actively publishing in the field, and
familiar with academic and proprietary research in pharmacology and
pharmacokinetics.  Evidence should be provided of research by the applicant in
previous or ongoing clinical trials, especially of a multicenter nature. 
Contributions in key areas such as protocol design, data analysis, and
interpretation are important.

Applicants who are current PPRU Principal Investigators should describe their
participation in Network research during the current award period.

New applicants should describe their research achievements and their
participation in randomized trials.

6) Evidence should be presented of the Units's adherence to the International
Conference on Harmonization (ICH) Good Clinical Practice guidelines adopted by
the FDA on May 9, 1997. Applicants should describe how the unit complies or
intends to comply with ICH Good Clinical Practice (FR 62:90, 1997).  A list
should be provided indicating the documents generated and filed before, during,
and after clinical trials.

7) Description of the equipment available and pharmacological studies performed
in the Pediatric Pharmacology Laboratory should be provided.  It should be stated
whether the laboratory is certified for Good Laboratory Practice by the FDA.

8) A description of the data management system used in clinical trials should be

9) A description of the standard operating procedures adopted in the Unit to
guide the activities needed to plan, conduct and manage single or multicenter
clinical trials should be provided.

10) A detailed description of the clinical and research capabilities of the PPRU
should be provided, including a description of pharmacokinetics and
pharmacodynamic capabilities and other strengths in pediatric pharmacology.

11) To provide peer reviewers and the NICHD an idea of the capabilities of the
Unit's investigators, new applicants must submit one or two examples of drug
evaluation studies that they would propose as Network protocols to the Network
Steering Committee (see Objectives 1 and 2).  These examples should be drafts (up
to 6 pages) for consideration by other participants in the program, and should
include enough detail (hypothesis, design, rationale, significance, procedures,
resources required, end points, power calculations, and discussion of
feasibility) to permit evaluation of the proposals for scientific merit.

12) Competing renewal applications as well as new applications should include one
or two examples of research protocols on specific aspects of pediatric
pharmacology that participating investigators intend to pursue if the PPRU is
funded (see Objectives 3 and 4).  These protocols should be presented in no more
than 6 pages.  Each should include a clearly identified hypothesis, brief
background information, and a narrative of the procedures to be employed.  They
should include details of statistical design and enough additional specific
material for a scientific review.  In addition, each protocol should provide a
brief justification of its need for PPRU resources.

13) An explicit statement of the applicant's preparedness to participate in PPRU
network clinical trials according to the terms of the RFA should be in the
application, and evidence of a long-term institutional commitment to the needs
of the PPRU is required.  This may take various forms, including (but not limited
to) the waiver of facility fees or bed costs for use of an outpatient clinic or
research ward for patients on protocol; equipment and space for a core
laboratory; released time for faculty to perform clinical pharmacology research
in children; and/or funding for support personnel.

14) Description of the training program in  pediatric clinical pharmacology and
in the conduct of pediatric drug trials. The description of the training program
should include a clinical and research component.  The training of nurses,
pharmacists and other health professionals in the conduct of pediatric drug
trials should be detailed. The objectives, design and the direction of the
research training program of the Associate Clinical Pharmacologist should be

Components of a PPRU

A.  Principal Investigator (PI)

The PI is expected to hold final authority and responsibility for the care of
PPRU patients, reporting only to the chief of pediatrics or the chairperson of
the pediatrics department, even though the regular care of the patients may be
in the hands of other investigators or house officers.  The PI must, therefore,
be state-licensed as a physician and board-certified in pediatrics. The PI may
be supported for up to 25 percent time and effort in the program, and may be
assisted by a part-time secretary (20 percent time and effort).

B.  Clinical Facility

A designated physical site where the clinical research will be performed is
required.  To allow optimal opportunities for collaboration among units in the
network, it is desirable that each PPRU have both inpatient and outpatient
capability.  These could be provided by a pediatric metabolic ward and an
outpatient clinic, a General Clinical Research Center (GCRC) funded by the NIH
National Center for Research Resources and suitable for admitting children and
caring for them as outpatients, or some other unit similarly equipped for
conducting pediatric clinical research.

Applicant institutions that wish to identify the GCRC as a site for conducting
PPRU research should include with the application a letter of agreement from the
GCRC program director or PI.

C. Core Laboratory

A funded PPRU may include a core laboratory dedicated to performing specialized
analyses and/or data management functions for studies conducted in the Unit. 
This should not include procedures routinely performed for a fee in institutional
laboratories or available in the laboratories of the investigators utilizing the

The core laboratory may be staffed by a PPRU-supported doctoral-level core
laboratory director (maximum 25 percent time and effort) and a core laboratory
technician (maximum 50 percent time and effort), if the science proposed so

The core laboratory director, who reports to the PI, should have responsibility
for quality control in that laboratory.  The time and effort of the laboratory
director may also be devoted to developing new methods for protocols being
conducted with PPRU support and to standardizing procedures to be carried out for
PPRU network collaborative protocols.  In addition, the core laboratory director
is responsible for the care and maintenance of the laboratory equipment, and will
cooperate with the PI in assisting other investigators in their use of the Unit.

D.  Other  Investigators

Any person with pediatric privileges at the grantee institution is eligible to
utilize the PPRU resources for studies of drug efficacy or metabolism, supported
from independent research funds, if the protocols have been approved and
prioritized by the Network Steering Committee.  These individual investigator
protocols must not delay or interfere with pursuit of the collaborative studies
that are the Unit's primary responsibility.  For investigators inexperienced in
clinical pharmacology, the PI is expected to provide advice and guidance. 
Clinical pharmacists are encouraged to participate in PPRU research in
collaboration with physicians who bear the responsibility for patient care. No
funds for Other Investigator are authorized.

E.  Nurse Coordinator and Research Nurse

A qualified nurse coordinator is one of the most important assets of a PPRU.  The
nurse coordinator reports to and takes direction from the PI, whether or not he
or she is a member of the institution's nursing service.  The nurse coordinator
(in cooperation with the associate clinical pharmacologist) carries out as many
parts of the research protocols as possible, dovetailing schedules for maximum
efficiency and instructing and supervising the other nursing staff in those
operations or procedures for which he or she is unavailable.  He or she is
responsible for data collection and organization, unless the latter
responsibility is assigned to a data coordinator (see below).  The nurse
coordinator is a full time position supported by the grant.

If the need arises an additional research nurse will assist the nurse coordinator
in all the facets of clinical trials.  One or more individuals may be supported
in the research nurse position, at a total of one full-time equivalent (100
percent time and effort).

F.  Patient Recruiter

A patient recruiter may be justified to insure the efficient recruitment of
patients required in Network protocols.  This individual maintains a registry of
potential study candidates, gathers recruitment information from different areas
of the hospital, clinics and private offices to match potential study patients
with specific protocols (up to 50 percent time and effort).

G.  Associate Clinical Pharmacologist

Units may request support for salaries and fringe benefits for this position
(maximum 50 percent time and effort).  The associate clinical pharmacologist may
be a physician who is fully trained in pediatrics, has completed subspecialty
training, and wishes to gain experience in the conduct of pediatric pharmacology
research under the guidance and supervision of the PI or some other appropriate
person.  Alternatively, the associate clinical pharmacologist may be a
non-physician holding the Pharm.D. degree or a Ph.D. in Pharmacology who has had
special training in pediatric pharmacology and wishes to obtain additional
supervised clinical experience.  Support for the associate clinical
pharmacologist from the PPRU is for research time and effort only, unless this
person is a licensed physician who assists the PI in supervising patient care in
the Unit.  A qualified individual may be supported for up to two years as an
associate clinical pharmacologist at a PPRU.

H.  Data Coordinator

Each PPRU application should include information about the data management system
to be used in the Unit for collaborative studies being performed by the Network. 
It is expected that each PPRU will serve as the data coordinating center for one
or more collaborative protocols.  If justified by the expected volume of work,
a data coordinator may be supported (up to 25 percent time and effort) by a PPRU
grant.  This person will organize the data in preparation for transmission to the
NICHD and other PPRUs when appropriate.  These functions are critical to the
success of the Network.

I.  Pharmacy

The availability of a pharmacy capable of supporting clinical research activities
and experienced in the preparation of materials for randomized clinical trials
should be documented.

J.  Budget preparation

Allowable costs in NIH cooperative agreements are governed by rules set forth in
the Public Health Service Grants Policy Statement and as stated on the Notice of
Grant Award.  Under these rules the PI may exercise flexibility to meet
unexpected requirements by rebudgeting or requesting approval to rebudget among
categories within the total direct cost budget of the PPRU (as shown on the
Notice of Grant Award), within the ceilings set in these guidelines.

PPRU grants are for five years, at a maximum level of $300,000 in total costs for
the first year.  They are renewable through competing continuation applications,
provided funds are available.  Competing continuations from existing PPRU's may
request an initial year increase of three percent above the level of the direct
costs for the final year of the last funding cycle.

Items supportable through a PPRU cooperative agreement award may include:

1.  Administration.  Personnel:  Principal investigator (maximum 25 percent time
and effort); secretary (maximum 25 percent time and effort).
Administrative Support Services:  supplies, duplication costs, telephone.
Travel:  PI, Associate PI's and Nurse Coordinator to meetings of the NSC.  Budget
personnel may attend up to two meetings each year if needed.

2.  Core Laboratory.  Personnel:  Core laboratory director (maximum 25 percent
time and effort); core laboratory technician (maximum 50 percent time and
effort).  Equipment: The equipment used in the core laboratory should be
primarily that available to the investigators or obtainable from institutional
resources. New equipment to up to a maximum of $50,000 total cost, distributed
over the first four years of the award may be requested in a PPRU cooperative
agreement, with appropriate justification.  Supplies: Appropriate for unit
participation in collaborative protocols and for support of specialized analyses
for investigator-initiated studies on the Unit.
Other:  Maintenance costs of equipment purchased with the award or otherwise
dedicated to Unit use.  The maximum allowable total annual amount for supplies
plus other in the core laboratory is $20,000.

3.  Research Services Core.  Personnel:  Nurse Coordinator and research nurse
(maximum 100 percent time and effort each); Associate Clinical Pharmacologist
(maximum 50 percent time and effort); Data Coordinator (maximum 25 percent time
and effort).

Each proposed Network protocol should include an estimate of staff time and
required hospital ancillary costs needed for the protocol.  (These costs should
NOT be included in the overall requested Unit budget, since they will be
distributed over all the Network participants in that protocol.)  For studies
performed in collaboration with pharmaceutical firms, those firms should pay the
fees for research-related clinical determinations.  For investigator-initiated
studies in which pharmaceutical firms do not participate, these costs must be
supported from sources other than the PPRU funding.

Studies of drugs already on the market with no commercial sponsors may be funded
through a capitation system.  Specific protocol-related costs will be capitated
according to the anticipated number of patients to be enrolled at the applicant
PPRU.  Level of funding will be based on actual recruitment.  Allocations for
this purpose will depend on the availability of funds.

For drug company-initiated protocols being pursued on the units, there must be
appropriate reimbursements from non-PPRU sources for core laboratory equipment
maintenance, supplies, and personnel time, as well as for data management costs. 
These reimbursements must be used to offset unit costs and should be reported as
grant-related income.

The following items are not fundable through a PPRU grant:
Costs of clinical care, such as patient bed costs, outpatient visit fees, and
clinical laboratory determinations.  These costs must be paid by the
pharmaceutical companies for protocols performed on their initiative or by
third-party carriers or other sources for investigator-initiated protocols.
Laboratory costs (outside the core laboratory) for projects being performed by
non-PPRU investigators using the Unit. Travel to scientific meetings or for any
other purpose except for the PI, associate PI's, Nurse Coordinator and budget
personnel  to attend meetings of the NSC.

Since applicants will be proposing at least two research plans, the individual
and the collaborative, the page limit for the Research Plan sections of the
application is 25 pages plus 6 pages for each proposed protocol.For questions
related to application format, applicants may contact one of the individuals

Submit a signed, typewritten original of the application, including the
Checklist, and three signed photocopies in one package to:

Center for Scientific Review
National Institutes of Health
6701 Rockledge Drive, Suite 1040, MSC 7710
Bethesda, MD  20892--7710
Bethesda, MD  20817 (for express/courier service)

At the time of submission, two additional copies of the application must be sent

Susan Streufert, Ph.D.
Division of Scientific Review
National Institute of Child Health and Human Development
6100 Executive Boulevard, Room 5E01 - MSC 7510
Bethesda, MD  20892-7510

Applications must be received by March 17, 1998.  If an application is received
after that date, it will be returned to the applicant without review. The Center
for Scientific Review (CSR) will not accept any application in response to this
RFA that is essentially the same as one currently pending initial review, unless
the applicant withdraws the pending application.  The CSR will not accept any
application that is essentially the same as one already reviewed. This does not
preclude the submission of substantial revisions of applications already reviewed
but such applications must include an introduction addressing the previous


Upon receipt, applications will be reviewed for completeness by the CSR and
responsiveness by the NICHD. Incomplete or non-responsive applications will be
returned to the applicant without further consideration.  Complete and responsive
applications will be evaluated for scientific and technical merit by an
appropriate peer review group convened by the NICHD in accordance with the review
criteria stated below.

As part of the initial merit review, a process may be used by the scientific
review group in which applications are determined to be competitive or non-
competitive based on their scientific merit relative to other applications
received in response to this RFA. Applications judged to be competitive will be
discussed and assigned a priority score. Applications determined to be non-
competitive will be withdrawn from further consideration and a summary statement
containing reviewers's comments will be sent to the PI.

Following initial peer review, applications will be evaluated by the National
Advisory Child Health and Human Development (NACHHD) Council for program
relevance and policy issues before awards are made.

Review criteria:

o  Qualifications and research experience of the PI and staff in clinical
pharmacology, a record of research productivity and a demonstrated interest in
pharmacological research in children.

o  An explicitly stated willingness by these investigators to generate protocols
to perform on the Unit, to propose protocols to the NSC for collaborative
pursuit, and to collaborate with pharmaceutical firms in testing useful drugs in
children is required.

o  Suitability of the proposed clinical locus for the Unit in the applicant
institution or its affiliated hospital, such as a pediatric metabolic ward and
outpatient clinic, a GCRC with staff accustomed to conducting studies in
children, or some unit similarly staffed and equipped.

o  Availability of and access to suitable populations to participate as research
subjects in PPRU studies.

o  Demonstrated ability of the PPRU to recruit patients for pediatric drug

o  Scientific and technical merit and relevance to the objectives of this RFA of
the sample protocols proposed for pursuit in the Network and in the local PPRU.

o  Evidence of previous successful research collaborations with industry or of
efforts to arrange future collaborations.

o  Adequacy of facilities, functions, and probable value to the research of any
proposed core laboratory.

o  Adequacy of clinical data management resources available to support PPRU

o  Evidence of compliance with the Good Clinical Practice and Good Laboratory
Practice guidelines that apply to investigators and/or institutions.

o  Evidence of institutional commitment to the long-term activities of the PPRU

o  Training environment including the institutional commitment, the quality of
the facilities and the availability of research support. 

o  Objectives, design and direction of the training program in clinical pediatric
pharmacology and pediatric drug trials.

o  Adequacy of plans to include both genders and minorities and their subgroups
as appropriate for the research.

o  Appropriateness of proposed budget and duration in relation to the proposed

The scientific review group will also examine the provisions for the protection
of human and animal subjects and the safety of the research environment.


The anticipated date of award is January 1, 1999.  Awards will be made on
scientific merit as determined by peer review.  The availability of appropriate
study populations, the extent of investigator experience, adequacy of equipment
and facilities, and program balance will also be taken into account.

Although this program is provided for in the financial plans of the NICHD, awards
pursuant to this RFA are contingent upon the availability of funds for this


Letter of Intent Receipt Date:          January 12, 1997
Application Receipt Date:               March 17, 1998
Review by NACHHD Council:               September 1998
Earliest Possible Award Date:           January 1, 1999


Written and telephone inquiries concerning this RFA are encouraged.  The
opportunity to clarify any issues or questions from potential applicants is

Direct inquiries regarding programmatic issues to:

George P. Giacoia M.D.
Endocrinology, Nutrition and Growth Branch
Center for Research for Mothers and Children
National Institute of Child Health and Human Development
6100 Executive Boulevard, Room 4B11 - MSC 7510
Bethesda, MD  20892-7510
Telephone:  (301) 496-5593

Direct inquiries regarding fiscal matters to:

Mary D. Tozzolo
Grants Management Branch
National Institute of Child Health and Human Development
6100 Executive Boulevard, Room 8A17 - MSC 7510
Bethesda, MD  20892-7510
Telephone:  (301) 496-1303


This program is described in the Catalog of Federal Domestic Assistance No.
93.865, Research for Mothers and Children.  Awards are made under authorization
of the Public Health Service Act, Section 301 (42 USC 421), and administered
under PHS grants policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part
74.  This program is not subject to the intergovernmental review requirements of
Executive Order 12372 or  Health Systems Agency review.

The PHS strongly encourages all and contract recipients to provide a smoke free
workplace and promote the non-use of all tobacco products.  In addition, Public
Law 103-227, the Pro- Children Act of 1994, prohibits smoking in certain
facilities (or, in some cases any portion of the facility) in which regular or
routine education, library, day care, health care or early childhood development
services are provided to children.  This is consistent with the PHS mission to
protect and advance the physical and mental health of the American people.

Return to Volume Index

Return to NIH Guide Main Index

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.